ReviewBJR artificial intelligence2026
Autonomous reporting of 'normal' chest X-rays by artificial intelligence in the United Kingdom; can we take the human out of the loop?
Review in BJR artificial intelligence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chest X-rays (CXRs) are the most commonly performed imaging investigation. In the UK, many centers experience reporting delays due to radiologist workforce shortages. Artificial intelligence (AI) tools capable of distinguishing "normal" from "abnormal" CXRs have emerged as a potential solution. If "normal" CXRs could be safely identified and reported without human input, a substantial portion of radiology workload could be reduced. This article examines the feasibility and implications of autonomous AI reporting of "normal" CXRs, using the United Kingdom as an example setting. Key issues include defining "normal," ensuring generalizability across populations, and managing the sensitivity-specificity trade-off. It also addresses legal and regulatory challenges, such as compliance with IR(ME)R and GDPR, and the lack of accountability frameworks for errors. Further considerations include the impact on radiologists practice, the need for robust post-market surveillance, and incorporation of patient perspectives. While the benefits are clear, adoption must be cautious, with strong governance, legal clarity, and rigorous clinical validation to ensure safe and sustainable use.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.